Phage Therapy for the Treatment of Urinary Tract Infection

Summary

This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of bacteriophage therapy to treat and prevent the recurrence of a drug-resistant urinary tract infection with serious long-term effects. This study will follow a minimally invasive phage therapy approach consisting of oral, topical (opening of the urethra) and bladder installations of a 3-phage cocktail comprised of HP3, HP3.1 and ES19.

Timeline

Start

2023-05-01

Primary completion

2023-07-28

Completion

2024-06-30

Drugs

Indications